CJC/Ipamorelin Blend
CJC-1295 No DAC / Ipamorelin (5mg+5mg)
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.238
Reference number
5mg+5mg
Lyophilized vial
Combined GHRH analog and GHRP. Studied for synergistic growth hormone release via complementary receptor mechanisms.
Origin
The CJC/Ipamorelin Blend combines CJC-1295 Without DAC (5mg) and Ipamorelin (5mg), pairing a growth hormone-releasing hormone (GHRH) analog with a growth hormone releasing peptide (GHRP). This combination addresses two distinct receptor systems involved in GH secretion — the GHRH receptor and the ghrelin receptor (GHS-R1a).
Research Lineage
The rationale for combining GHRH and GHRP compounds is well-established in neuroendocrine research. Bowers, Veldhuis, and others demonstrated in the 1990s that GHRH and GHRPs act synergistically — their combined GH-releasing effect exceeds the sum of individual effects. This synergy arises from their complementary mechanisms at the hypothalamic and pituitary levels.
Mechanism of Action
CJC-1295 (Modified GRF 1-29) activates the GHRH receptor on pituitary somatotrophs via cAMP/PKA signaling. Ipamorelin activates the GHS-R1a (ghrelin receptor) via a phospholipase C pathway. These two pathways converge on GH vesicle exocytosis through distinct intracellular cascades, producing a synergistic amplification of GH release that has been documented in multiple pharmacological studies.
Components
CJC-1295 Without DAC (5mg) / Ipamorelin (5mg)
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.